ANDA 202366, held by Zydus Healthcare. Lansoprazole.
As of Nov 21, 2026, ANDA 202366 (Lansoprazole), held by Zydus Healthcare, was first approved by FDA on Aug 19, 2013, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2013 | Original application | Approved | None posted |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Nov 24, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 24, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 24, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 24, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 24, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 16, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 19, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters